SHH and basal cell carcinoma: An inhibitor of the canonical Shh signaling pathway, the smoothened receptorinhibitor vismodegib, has been approved for the treatment of the most commonform of skin cancer, basal cell carcinoma (metastatic and inoperable diseaseforms), or in cases of relapse after surgical treatment and radiotherapy [254].